Takeda Pharmaceutical Company has received approval from the Japanese Ministry of Health, Labour and Welfare for its new drug application for NESINA (alogliptin), a DPP-4 inhibitor for the treatment of type 2 diabetes.

The drug was co-developed by Takeda and PPD‘s compound partnering division.

PPD is entitled to a $7.5m milestone payment from Takeda following necessary regulatory and pricing approvals in Japan.

With the regulatory approval received for the new drug application, the partners are awaiting the pricing approval in Japan, when PPD will become eligible to receive the payment.